Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Selected Financial Data
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Statement

Pfizer Inc., selected items from income statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Revenues exhibited considerable fluctuation over the period. Initial revenues of approximately $51.3 billion in 2005 decreased to around $48.4 billion by 2007, remaining relatively stable through 2009 at approximately $50 billion. A significant increase was then observed in 2010, reaching $67.8 billion, followed by a decline to $58.9 billion in 2012. Revenues continued to decrease, reaching a low of $49.6 billion in 2014, before a modest recovery to $52.8 billion in 2016. A substantial surge occurred in 2021, with revenues reaching $101.2 billion, followed by a sharp decrease to $59.6 billion in 2022 and a slight increase to $63.6 billion in 2023, and $62.6 billion in 2024. Finally, revenues reached $62.6 billion in 2025.

Net Income Trend
Net income attributable to Pfizer Inc. demonstrated volatility throughout the analyzed period. Starting at $8.1 billion in 2005, it peaked dramatically in 2006 at $19.3 billion, before falling back to $8.1 billion in 2007. Net income remained relatively stable between $8.1 billion and $10.0 billion from 2007 to 2011. A substantial increase was observed in 2012, reaching $14.6 billion, followed by a further increase to $22.0 billion in 2013. A significant decline occurred in 2014, dropping to $9.1 billion, and continued to fall to $6.96 billion in 2015. A modest recovery occurred in 2016, reaching $7.2 billion, before a large increase to $21.3 billion in 2017. Net income decreased to $11.2 billion in 2018, then increased to $16.3 billion in 2019, before decreasing to $9.6 billion in 2020. A substantial increase was observed in 2021, reaching $22.0 billion, followed by a further increase to $31.4 billion in 2022. A dramatic decrease occurred in 2023, dropping to $2.1 billion, before a recovery to $8.0 billion in 2024, and $7.8 billion in 2025.

The relationship between revenues and net income does not appear consistently correlated. While increases in revenue often corresponded with increases in net income, this was not always the case, particularly in the later years of the period. The substantial revenue increase in 2021 and 2022 did not translate into a proportional increase in net income, and the revenue decrease in 2023 was accompanied by a dramatic decrease in net income. This suggests that cost of goods sold, operating expenses, or other factors significantly impacted profitability during those periods.

Volatility
Both revenue and net income exhibited significant volatility throughout the period. The fluctuations suggest the company may be subject to external factors, such as patent expirations, competition, or changes in market demand, or internal factors such as strategic shifts or significant acquisitions/divestitures. The large swings in net income, particularly in relation to revenue, indicate a sensitivity to cost management and operational efficiency.

The period from 2020 to 2023 demonstrates a particularly notable shift in both revenue and net income, with a large increase followed by a substantial decline. Further investigation would be required to determine the underlying causes of these changes, such as the impact of specific products, acquisitions, or macroeconomic conditions.


Balance Sheet: Assets

Pfizer Inc., selected items from assets, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The asset base of the company exhibited significant fluctuations between 2005 and 2025. Initial observations reveal a period of relative stability followed by substantial growth, and then a subsequent period of contraction and stabilization. Current assets and total assets generally moved in the same direction, indicating a consistent relationship between these components of the balance sheet.

Total Assets Trend (2005-2025)
From 2005 to 2008, total assets experienced a modest decline from $117.565 billion to $111.148 billion. A dramatic increase occurred between 2008 and 2009, surging to $212.949 billion. This was followed by a decrease in 2010 to $195.014 billion, continuing a downward trend to $169.274 billion by 2014. Assets remained relatively stable between $167.460 billion and $171.797 billion from 2014 to 2017, before declining to $159.422 billion in 2018. A recovery was observed in 2019, reaching $167.489 billion, but this was followed by a decrease to $154.229 billion in 2020. A substantial increase occurred in 2021 and 2022, reaching $181.476 billion and $226.501 billion respectively, before decreasing to $213.396 billion in 2023 and $208.160 billion in 2024. A slight increase to $208.160 billion was observed in 2025.
Current Assets Trend (2005-2025)
Current assets began at $41.896 billion in 2005 and increased to $46.949 billion in 2006. They remained relatively stable around the $46-47 billion mark for the next two years, before decreasing to $43.076 billion in 2008. A significant increase was observed in 2009, reaching $61.670 billion, followed by a slight decrease to $60.468 billion in 2010. Current assets then decreased steadily through 2016, reaching $38.949 billion. A modest recovery occurred in 2017, reaching $41.141 billion, followed by a larger increase to $49.926 billion in 2018. A substantial decrease was observed in 2019, falling to $32.803 billion, followed by a slight increase to $35.067 billion in 2020. A significant increase occurred in 2021, reaching $59.693 billion, followed by a decrease to $51.259 billion in 2022. Current assets decreased to $43.333 billion in 2023 and $50.358 billion in 2024, before decreasing to $42.898 billion in 2025.

The most substantial change in total assets occurred between 2008 and 2009, suggesting a significant event such as an acquisition or a major restructuring. The period from 2014 to 2017 demonstrates a period of relative stability in total assets, while the fluctuations in current assets throughout the period indicate changes in short-term liquidity and operational needs. The increases observed in 2021 and 2022, followed by a decrease in 2023 and 2024, suggest a recent shift in asset allocation or business strategy.


Balance Sheet: Liabilities and Stockholders’ Equity

Pfizer Inc., selected items from liabilities and stockholders’ equity, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


An examination of the provided financial information reveals notable shifts in the company’s liabilities and stockholders’ equity between 2005 and 2025. Overall, a period of increasing complexity in the capital structure is apparent, punctuated by significant fluctuations, particularly in total liabilities.

Current Liabilities
Current liabilities exhibited considerable volatility throughout the period. After initially decreasing from 2005 to 2006, they generally trended upward until 2016, peaking at US$31.115 billion. A subsequent decline was observed through 2018, followed by a substantial increase in 2019 to US$37.304 billion. A significant drop occurred in 2020, decreasing to US$25.920 billion, before rising again to US$47.794 billion in 2022 and decreasing to US$36.984 billion in 2025. This suggests a dynamic management of short-term obligations, potentially influenced by operational cycles and financing activities.
Total Liabilities
Total liabilities demonstrated a dramatic increase between 2005 and 2009, surging from US$51.938 billion to US$122.503 billion. This was followed by a period of decline, reaching US$95.481 billion in 2013. Liabilities remained relatively stable between 2013 and 2018, fluctuating between US$95.481 billion and US$104.042 billion. A substantial increase occurred in 2022, reaching US$137.213 billion, before decreasing to US$124.899 billion in 2023 and US$121.385 billion in 2025. The large increase in 2009 likely reflects a significant event, such as a major acquisition or restructuring, requiring substantial financing.
Total Debt
Total debt followed a similar pattern to total liabilities, with a notable increase between 2005 and 2009, rising from US$17.936 billion to US$48.662 billion. Debt levels then decreased through 2013, stabilizing around US$36-43 billion until 2018. A rise to US$52.150 billion occurred in 2019, followed by a decrease to US$35.829 billion in 2020. A significant increase was observed in 2022, reaching US$71.888 billion, before decreasing to US$64.351 billion in 2023 and US$64.795 billion in 2025. The correlation between total debt and total liabilities suggests that debt financing is a primary component of the company’s capital structure.
Total Stockholders’ Equity
Total stockholders’ equity initially increased from 2005 to 2006, then decreased from 2006 to 2009. It subsequently recovered, peaking at US$90.014 billion in 2009, before generally declining through 2015. Equity then experienced a recovery, reaching US$77.201 billion in 2021, followed by an increase to US$95.661 billion in 2022. A decline was observed in 2023 and 2025, reaching US$88.203 billion and US$86.476 billion respectively. The fluctuations in equity likely reflect profitability, dividend payments, and share repurchase programs.

The observed trends indicate a complex financial profile. The significant increases in both total liabilities and total debt, particularly around 2009 and 2022, warrant further investigation to understand the underlying drivers. The fluctuations in stockholders’ equity suggest a dynamic capital management strategy. The interplay between debt and equity levels will be crucial in assessing the company’s long-term financial health and risk profile.


Cash Flow Statement

Pfizer Inc., selected items from cash flow statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Over the period examined, the company’s cash flow statement reveals significant fluctuations across all three activities: operating, investing, and financing. A general pattern of volatility is apparent, with notable shifts in cash flow generation and usage occurring throughout the timeframe.

Operating Activities
Net cash provided by operating activities demonstrated considerable variability. Initial values were strong, peaking around US$17.6 billion in 2006, followed by a decline and subsequent recovery. A substantial increase is observed in 2021 (US$32.9 billion) and 2022 (US$29.3 billion), likely influenced by specific events during those years. However, a significant decrease occurred in 2023 (US$8.7 billion) before a partial recovery in 2024 and 2025. Overall, operating cash flow remained positive throughout the period, indicating the core business generally generated cash.
Investing Activities
Net cash flow from investing activities exhibited the most pronounced fluctuations. The company transitioned between periods of cash outflow and inflow. Significant outflows occurred in 2008 and 2009, reaching a peak outflow of US$31.3 billion in 2009. Periods of inflow were observed in 2006, 2007, 2011, and 2012, and again in 2018 and 2025, though the inflows were generally smaller in magnitude than the outflows. A substantial outflow is noted in 2023 (US$22.5 billion) and 2024 (US$32.3 billion), suggesting significant capital expenditures or acquisitions during those periods. These swings suggest active portfolio management, including acquisitions, divestitures, and capital investments.
Financing Activities
Net cash flow from financing activities also showed substantial variation. Large outflows were common in the earlier part of the period, particularly in 2006 (US$23.1 billion) and 2011 (US$20.6 billion), potentially related to debt repayment or share repurchases. A significant inflow occurred in 2009 (US$14.5 billion), possibly from debt issuance. The later years demonstrate a pattern of consistent, though often substantial, outflows, with a notable inflow in 2023 (US$26.1 billion). This suggests the company frequently utilizes financing to support its operations and investments, and occasionally benefits from capital raising activities.

The interplay between these three activities reveals a complex financial profile. Periods of strong operating cash flow were often offset by significant investing or financing activities. The large swings in investing and financing cash flows suggest a proactive approach to capital allocation and financial management. The recent trends, particularly the substantial operating cash flow in 2021 and 2022 followed by a decline in 2023, warrant further investigation to understand the underlying drivers.


Per Share Data

Pfizer Inc., selected data per share, long-term trends

US$

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1, 2, 3 Data adjusted for splits and stock dividends.


The per share financial information reveals fluctuating performance over the period examined. Basic and diluted earnings per share (EPS) demonstrate considerable variability, while dividend per share exhibits a generally increasing trend, albeit with some interruptions.

Earnings Per Share (EPS)
Both basic and diluted EPS followed a similar pattern. A significant increase occurred between 2005 and 2006, followed by a decline in 2007. EPS remained relatively stable between 2007 and 2009. A substantial rise was then observed in 2012 and again in 2017, with peaks in both years. Following 2017, EPS decreased in 2018, recovered in 2019, and then experienced another surge in 2021, reaching its highest point in the observed period. A dramatic decrease occurred in 2022, followed by a partial recovery in 2023 and 2024. The 2025 value shows a slight increase from 2024.
Dividend Per Share
Dividend per share generally trended upward from 2005 to 2019, demonstrating a commitment to returning value to shareholders. The increase was not linear, with a noticeable dip in 2009. Growth slowed between 2019 and 2021, and continued at a similar pace through 2025. The dividend remained consistently positive throughout the entire period.

The relationship between EPS and dividend per share is not consistently aligned. While dividends generally increased, EPS experienced more pronounced fluctuations. There were periods where dividends continued to rise despite declining EPS, suggesting the company may have prioritized maintaining shareholder returns even during less profitable years. The significant drop in EPS in 2022 did not immediately translate into a reduction in dividend, indicating a potential buffer or strategic decision to maintain dividend payments.

The volatility in EPS suggests the company’s profitability is sensitive to various factors, potentially including market conditions, product performance, and research and development outcomes. The consistent growth in dividends, despite these fluctuations, suggests a stable financial policy regarding shareholder distributions.